logo

For the Inventor, By the Inventor

Eugene, OR, United States of America

John F W Keana

This inventor holds 28 USPTO granted patents, plus 1 CIPO patent, primarily in Pharmaceutical Compounds. Top assignees: Cytovia, Inc., The Salk Institute, Euro-Celtique S.a.. Active years: 2001-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John F W Keana. Retrieved from https://idiyas.com/inventor/john-f-w-keana

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 28

% Patents Active = 75.0


Average Co-Inventor Count = 5.4

ph-index = 9

Forward Citations = 406(Granted Patents)


Company Filing History:

goldMedal7 out of 47 
 
Cytovia, Inc.
 patents
silverMedal7 out of 593 
 
The Salk Institute
 patents
bronzeMedal5 out of 270 
 
Euro-Celtique S.a.
 patents
4. 4 out of 276 
 
The University of Sydney
 patents
5. 3 out of 20 
 
Mitobridge, Inc.
 patents
6. 2 out of 2 
 
Cascade Prodrug Inc.
 patents
7. 1 out of 526 
 
Oregon Health & Science University
 patents
8. 1 out of 3,546 
 
University of Michigan
 patents
9. 1 out of 145 
 
University of Oregon
 patents
10. 4 out of 834,601 
Other
 patents
where one patent can have more than one assignee

Years Active: 2001-2022

Loading Chart...
Loading Chart...
Areas of Expertise:
PPAR Agonists
Apoptosis Inhibitors
NMDA Receptor Ligands
Vinca Alkaloids
Fluorogenic Reporter Molecules
Dipeptide Inhibitors
Quinoxalinediones
Carbocyclic Compounds
5-Oxo Tetrahydro Benzopyrans
Thiosemicarbazones
Guanidines
Caspases
28 patents (USPTO):Explore Patents
1. 11440889 - Analogs of fexaramine and methods of making and using (2022-09-13),
2. 11420934 - PPAR agonists (2022-08-23),
3. 10815203 - Analogs of fexaramine and methods of making and using (2020-10-27),
4. 10550071 - PPAR agonists (2020-02-04),
5. 10450277 - Analogs of fexaramine and methods of making and using (2019-10-22),
6. 10301268 - Analogs of fexaramine and methods of making and using (2019-05-28),
7. 9938234 - PPAR agonists (2018-04-10),
8. 8883775 - Treatment of hyperproliferative diseases with vinca alkaloid N-oxide analogs (2014-11-11),
9. 8410075 - Mannich base N-oxide drugs (2013-04-02),
10. 8048872 - Treatment of hyperproliferative diseases with vinca alkaloid N-oxide and analogs (2011-11-01),
11. 7557251 - Production of gossypol co-crystals (2009-07-07),
12. 7270801 - Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for caspases and other enzymes and the use thereof (2007-09-18),
13. 6949516 - Dipeptide apoptosis inhibitors and the use thereof (2005-09-27),
14. 6800657 - Substituted 5-oxo-5, 6, 7, 8-tetrahydro-4H-1-benzopyrans (2004-10-05),
15. 6759207 - Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for caspases and other enzymes and the use thereof (2004-07-06),

Title: John F W Keana: Innovator in Metabolic Disorders and Inflammation Treatment

Introduction

John F W Keana, based in Eugene, Oregon, is a prolific inventor with a remarkable portfolio of 28 patents. His innovations primarily focus on the treatment and prevention of metabolic disorders and inflammation, demonstrating a significant contribution to the fields of medical science and pharmacology.

Latest Patents

Among his latest patents, Keana has developed novel compounds, including analogs of fexaramine, and methods related to their application. These compounds are designed to activate FXR receptors in the intestines, effectively treating or preventing metabolic disorders when administered therapeutically. Additionally, his patents elaborate on treatment methods for inflammation in the intestinal region by utilizing these compounds, showcasing his commitment to improving gastrointestinal health.

Career Highlights

Throughout his career, Keana has made impactful contributions while working at notable institutions such as Cytovia, Inc. and the Salk Institute for Biological Studies. His work at these organizations has further propelled advancements in understanding and treating metabolic and inflammatory diseases.

Collaborations

Keana has collaborated with esteemed colleagues, including Sui Xiong Cai and Eckard Weber. These partnerships highlight the collaborative nature of innovation and the shared pursuit of groundbreaking solutions in the medical field.

Conclusion

John F W Keana's impressive record of 28 patents signifies his vital role as an innovator in the pharmaceutical industry. His dedication to developing effective treatments for metabolic disorders and inflammation reflects the importance of continuous research and innovation in improving human health.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…